None listed
Conditions
Brief summary
This double-blind, randomised, placebo controlled trial will examine the safety and efficacy of intranasal oxytocin for the treatment of cannabis and alcohol dependence. It is hypothesised that participants randomised to the oxytocin condition, compared to participants randomised to the placebo condition will have a higher rate of treatment completion, experience reduced number, severity, and duration of cannabis and alcohol withdrawal symptoms and will report fewer days of cannabis and alcohol use at one month follow-up.
Sponsors
University of Sydney
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used)
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Diagnostic and Statistical Manual for Mental Disorders-IV diagnostic criteria for cannabis and alcohol dependence.
Exclusion criteria
Epilepsy Severe depression with suicidal thoughts and/ or actions Drug addiction (other than nicotine, cannabis, or alcohol) Currently take medication and you are not stable on this medication (i.e., have been taking the medication for less than 4 weeks) Are currently receiving psychological or pharmacological treatment for substance use problems Kidney Disease- (i.e., kidney stones, recurrent bladder infections, or known kidney failure). Severe liver disease (e.g., decompensated hepatic failure) Sensitivity to preservatives (in particular E 216, E 218 and chlorobutanol hemihydrate). Nasal obstruction, discharge, or bleeding Cardiovascular problems (e.g., heart disease, history of heart attacks), high blood pressure (hypertension) Habitually drink large volumes of water Pregnancy
Outcome results
None listed